US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer’s drug significantly slowed cognitive and functional decline, results hailed as “remarkable” by experts despite some patients experiencing serious side effects.
In an analysis of nearly 1,200 people in the early stages of the disease, donanemab slowed the progression of symptoms by 35 percent over a period of 18 months compared to placebo.
NigeriaDNA is a Direct News source that delivers the latest news, buzz, and stories from some of Nigeria’s most popular and trusted news websites. NigeriaDNA facilitates this by publishing headlines linking to breaking news and curated snippets from a diverse range of Nigerian credible, independent, and public-interest news sources. Our editors make it easy for Nigerians abroad and diaspora to discover top news stories in real-time as they're posted and directly linked to Nigeria's authoritative News Sources.
© 2024 All Rights Reserved | Curated and Powered by Nigeria DNA
